Marksans Pharma arm adds Metformin Hydrochloride 500mg/ 5 ml Oral Solution to growing list of UK approved medicines
Mumbai: Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited has received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
Metformin is widely used as a first-line treatment for type 2 diabetes, and this approval strengthens Relonchem’s presence in the UK oral antidiabetic drug market.
This marks the third regulatory approval granted to Relonchem in the UK this month. Earlier in May, the company received marketing authorization for Sennosides 7.5 mg Tablets and Gabapentin 50 mg/ml Oral Solution.
Read also: Marksans Pharma arm Relonchem gets marketing authorization for Sennosides Tablets in UK
In March 2025, Relonchem had also received UK MHRA approval for Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.